Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790279 · ClinicalTrials.gov registry record · Phase 4
Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- Phase 4
- Development phase
- 175
- Enrollment target
NCT04790279 is a Phase 4 study that has completed, run by Prisma Health-Upstate. The registered enrollment target is 175 participants.
The verdict
NCT04790279, a Phase 4 study, has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 175 participants
- Enrollment target
Study Summary
A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol and nifedipine ER being the most commonly used medications. While these medications are both effective, they are not without limitations. Amlodipine is a medication in the same class as nifedipine ER. It is a first-line antihypertensive in the general population. It tends to have less side effects than nifedipine ER. It has not been studied specifically in postpartum women. The purpose of this study is to determine if amlodipine is noninferior to nifedipine ER in managing hypertension in the postpartum period.
Interventions
- DRUG Amlodipine
- DRUG NIFEdipine ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2023-01-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04790279
The ClinicalTrials.gov registry entry for NCT04790279 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prisma Health-Upstate, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Amlodipine is the first listed.
NCT04790279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04790279 about?
NCT04790279 is a clinical study titled "Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension". A significant number of pregnancies are complicated by hypertensive disorders. Hypertension often worsens in the postpartum period and many women need started on medications. Currently, recommended medications for blood pressure management in pregnant and postpartum women are limited, with labetalol...
What is the current status of trial NCT04790279?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 175 participants. The study started on 2021-04-09. Estimated completion is 2023-01-25.
What interventions are being tested in trial NCT04790279?
The interventions under investigation include: Amlodipine (DRUG), NIFEdipine ER (DRUG).
Who is sponsoring clinical trial NCT04790279?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.